A Phase IIB study demonstrated dose-dependent increases in bone mineral density (BMD) at the total hip, lumbar spine, and femoral neck fracture sites in postmenopausal women with low BMD. Odanacatib selectively inhibits cathepsin K, a key enzyme in osteoclastic bone resorption.
JANUVIA showed longer-term efficacy and safety profile in combination therapy with metformin, improving glycemic control in patients with type 2 diabetes. Additionally, the study demonstrated that JANUVIA provided glycemic control regardless of baseline characteristics.
Results from two Phase II studies support the efficacy profile of sitagliptin, a novel DPP-IV inhibitor, improving glycaemic control in patients with type 2 diabetes. Treatment with sitagliptin resulted in no significant weight gain and a low risk of hypoglycaemia.
The partnership aims to stimulate and accelerate European research into beta cell function and survival, aiming to move towards a cure for diabetes. Approximately 194 million people worldwide suffer from diabetes, with the number expected to exceed 333 million by 2025.